Pharmexa A/S has appointed Achim Kaufhold to a newly created position of Executive Vice President, Chief Scientific Officer and Chief Medical Officer. Pharmexa is a Danish biotech company with a proprietary peptide vaccine targeting telomerase in Phase 3 and a recombinant protein vaccine targeting HER-2 in Phase 2.
Prof. Kaufhold was previously CMO at Chiron, now part of the Novartis group. He has been professor of microbiology and infectious diseases and a member of the Faculty of Medicine at the University of Aachen in Germany since 1993.
Source:
- Pharmexa press release, 18 September 2007
Copyright 2007 Evernow Publishing Ltd